New shot could help kids with tough leukemia

NCT ID NCT07134088

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 07, 2026 · Updated 17 times

Summary

This study tests a subcutaneous (under-the-skin) shot of blinatumomab in children under 12 with relapsed/refractory or minimal residual disease positive B-cell acute lymphoblastic leukemia. The goal is to see if the shot is safe and helps achieve remission. About 104 children will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Childrens Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Kanagawa Childrens Medical Center
RECRUITING

Yokohami-shi, Kanagawa, 232-8555, Japan
Seattle Childrens Hospital
RECRUITING

Seattle, Washington, 98105, United States
St Jude Childrens Research Hospital
RECRUITING

Memphis, Tennessee, 38105, United States

Conditions

Explore the condition pages connected to this study.

MINIMAL RESIDUAL DISEASE + B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA MINIMAL RESIDUAL DISEASE + B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA